Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension of rosuvastatin in children and adolescents with homozygous familial hypercholesterolemia
2014-004746-99Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rosuvastatin in homozygous familial hypercholesterolemia (HoFH), sponsored by AstraZeneca. Primary endpoint: Safety. Started Dec 2014; status: completed.
02
Drugs
rosuvastatin
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2014-004746-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004746-99.